(Q32090597)

6 July 2017

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome (English)

1 reference

6 July 2017

0 references

1 reference

irritable bowel syndrome

1 reference

1 reference

Watson ME

1

1 reference

6 July 2017

Lacey L

2

1 reference

6 July 2017

Kong S

3

1 reference

6 July 2017

Northcutt AR

4

1 reference

6 July 2017

McSorley D

5

1 reference

6 July 2017

Hahn B

6

1 reference

6 July 2017

Mangel AW

7

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

The American Journal of Gastroenterology

6 July 2017

1 reference

6 July 2017

96

1 reference

6 July 2017

2

1 reference

6 July 2017

455-459

1 reference

Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome.

6 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Clinical economics review: irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Towards a better understanding of patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Measurement of health status. Ascertaining the minimal clinically important difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Quality of life in persons with irritable bowel syndrome: development and validation of a new measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

Quality of life in irritable bowel syndrome, effect of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03525.X

10.1111/J.1572-0241.2001.03525.X

21 January 2018

Identifiers

DOI

1 reference

6 July 2017

1 reference